Clene Reports Q3 2026 Results, $3.9 Million Net Income
Clene reported Q3 2026 revenue of $56,000 and net income of $3.9 million, improving from a $8.8 million loss in the prior year. The company's operating loss was $6.3 million, with net income boosted by a $10.9 million favorable change in warrant and derivative liabilities. Clene submitted an NDA for accelerated approval of CNM-Au8 for ALS, with a Phase 3 trial planned for Q2 2027. The company has $9.9 million in cash and expects resources to last through mid-Q1 2027.
How this was made

The 30-second read
Why it matters
The earnings surprise could trigger short covering and modest buying in the thinly‑traded stock, but the small scale limits broader market impact.
Market read
Microcap earnings surprise with modest cash runway; limited but actionable for niche traders.
What to watch
The favorable shift in warrant and derivative liabilities contributed significantly to net income and may not repeat.
Background
Clene Inc. (CLNN) filed an 8‑K reporting its Q3 2026 results, showing a profit swing and cash sufficient through mid‑Q1 2027, and disclosed an NDA for accelerated FDA approval of its ALS therapy.
Ticker impact
Clene reported Q3 2026 revenue of $56,000 and net income of $3.9 million, a swing from a loss a year earlier.
modest upside as market prices in the profit swing and cash runway through Q1 2027
The company turned a loss into profit and disclosed sufficient cash to fund operations, which may attract short-covering and speculative buying in a thinly‑traded microcap.
Market effects
Limited impact; biotech microcaps may see slight interest from investors seeking earnings surprises.
Primarily U.S. OTC/OTC‑Q market; no broader regional effect.
Minimal; the news is confined to the company and does not affect global markets.
Counterpoint
Given the tiny revenue base, the profit may be a one‑off accounting effect rather than sustainable growth.
Key entities
- companyClene Inc.
Biotech firm reporting Q3 2026 earnings and filing an NDA for ALS therapy.